BioNTech’s $650 Million R&D Quarter: Shareholders Back Board Expansion as Market Awaits Lung Cancer Data

Despite sitting on nearly $20 billion in cash, BioNTech is burning through money at an accelerating pace as it races to reposition itself for the post-Covid era. Research and development costs surged past $650 million in the first quarter alone, while vaccine revenue – the engine that once propelled the company – shrank to just $138 million. The result was a substantial net loss, underscoring the financial strain of a transition that hinges entirely on clinical success.

Shareholders have thrown their weight behind the strategy. At the annual general meeting on 15 May 2026, 92% of the share capital was represented, and investors approved every management proposal. The supervisory board will now expand from six to eight members, with Iris Löw-Friedrich and Susanne Schaffert – both seasoned oncology executives – joining the oversight body. An accompanying resolution authorised the creation of new capital worth up to 50% of the current share base, giving the board flexibility to fund the swelling pipeline.

The revenue picture underscores the depth of the pivot. BioNTech reported first-quarter revenues of just €118.1 million, down from €182.8 million a year earlier. The company is sticking to its full-year guidance of $2.3 billion to $2.6 billion in total revenue, while simultaneously running a share buyback programme of up to $1.0 billion. For now, the market remains unimpressed.

The stock closed at €76.95 on Friday, shedding 2.22% on the day. It has lost 8.01% over the past month and sits roughly 7% lower since the start of 2026. Technically, the shares are trading below their key moving averages, with the gap to the long-term average exceeding eleven percentage points – a sign that institutional conviction has yet to return.

Should investors sell immediately? Or is it worth buying BioNTech?

The next major catalyst is just weeks away. On 21 May, the embargo lifts for abstracts to be presented at the ASCO annual meeting in Chicago. BioNTech will release Phase 2 data from the ROSETTA-Lung-02 study on 29 May, testing its experimental bispecific antibody Pumitamig in combination with chemotherapy against the established standard of care, Merck’s Keytruda (pembrolizumab). Success in first-line non-small cell lung cancer would send a powerful signal to both the analyst community and a skeptical investor base.

That divergence is already baked into analyst price targets. Canaccord keeps a “Buy” rating with a $158 target, while Leerink is far more cautious at just $94. The spread reflects how heavily the stock’s valuation has become tethered to the outcome of these clinical readouts.

The Pumitamig data marks only the beginning. BioNTech has mapped out seven late-stage oncology data readouts for this year and expects to have fifteen Phase 3 clinical trials running by year-end. A convincing result from ROSETTA-Lung-02 would provide the clinical underpinning for a strategic overhaul that has so far been backed by shareholders but ignored by the market.